Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer/Esperion Deal Reunites Lipitor Team; $1.3 Bil. Buys Two HDL Agents

Executive Summary

Pfizer's $1.3 bil. acquisition of Esperion will reunite the Lipitor research team and give Pfizer two more chances to develop a novel mechanism anti-atherosclerotic agent

You may also be interested in...



Pfizer Deals With Incyte, NicOx Reflect Emphasis On External Partnerships

Pfizer appears to be closing out the year with a stepped-up emphasis on external partnerships through recent deals with Incyte and NicOx

Pfizer Deals With Incyte, NicOx Reflect Emphasis On External Partnerships

Pfizer appears to be closing out the year with a stepped-up emphasis on external partnerships through recent deals with Incyte and NicOx

Pfizer Torcetrapib Phase III Program Will Cost $800 Mil.

Pfizer is spending $800 mil. on the Phase III development program for the cholesterol agent torcetrapib, Worldwide Development President Joe Feczko, MD, said during a Nov. 30 analysts meeting in Groton, Conn

Related Content

UsernamePublicRestriction

Register

PS043105

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel